Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma

Stopped early · Phase 1

Conditions studied: Previously Untreated Pancreatic Ductal Adenocarcinoma, Relapsed/Refractory Pancreatic Ductal Adenocarcinoma

In brief

The primary objective of this study is to evaluate the safety of single agent idelalisib and to evaluate safety and define the maximum tolerated dose (MTD) of idelalisib in combination with chemotherapy in adults with metastatic pancreatic ductal adenocarcinoma.

Key facts

Study ID

NCT02468557

Run by

Gilead Sciences

People needed

16

Starts

2015-07-30

Expected to finish

2016-04-27

Last updated by the study team

2021-04-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Scottsdale Healthcare Clinical Research Institute — Scottsdale, Arizona, United States
• Cedars Sinai Medical Center — Los Angeles, California, United States
• University of Colorado Cancer Center — Aurora, Colorado, United States
• Georgetown University — Washington D.C., District of Columbia, United States
• Indiana University Goshen Center for Cancer Care — Goshen, Indiana, United States
• Dana Farber/ Harvard Cancer Institute — Boston, Massachusetts, United States
• University of Rochester — Rochester, New York, United States
• Greenville Hospital System — Greenville, South Carolina, United States
• Mary Crowley Medical Research Center — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.